Steen JA, et al. (2008) Different phosphorylation states of the anaphase promoting complex in response to antimitotic drugs: a quantitative proteomic analysis. Proc Natl Acad Sci U S A 105, 6069-74 18420821

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T118-p - APC1 (human) ▲

Modsite: LAVYKAFtVDSPVQQ SwissProt Entrez-Gene Orthologous residues APC1 (human): T118‑p, APC1 (mouse): T118‑p, APC1 (rat): T118‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium)

S202-p - APC1 (human) ▲

Modsite: SHEVPPGsPREPLPT SwissProt Entrez-Gene Orthologous residues APC1 (human): S202‑p, APC1 (mouse): L202‑p, APC1 (rat): L202‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M), monastrol (preceded by thymidine block, then 4 hr fresh medium), nocodazole (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium), vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes vincristine increase

S233-p - APC1 (human) ▲

Modsite: KSGSLFGsSRVQYVV SwissProt Entrez-Gene Orthologous residues APC1 (human): S233‑p, APC1 (mouse): S233‑p, APC1 (rat): S233‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium), taxol, high dose (preceded by thymidine block, then 4 hr fresh medium)

T291-p - APC1 (human) ▲

Modsite: kFsEQGGtPQNVATS SwissProt Entrez-Gene Orthologous residues APC1 (human): T291‑p, APC1 (mouse): T291‑p, APC1 (rat): T291‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase

S341-p - APC1 (human) ▲

Modsite: sPsLHsRsPsIsNMA SwissProt Entrez-Gene Orthologous residues APC1 (human): S341‑p, APC1 (mouse): S341‑p, APC1 (rat): S341‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, S-phase (thymidine block, release into S), taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase thymidine decrease

S355-p - APC1 (human) ▲

Modsite: AALsrAHsPALGVHs SwissProt Entrez-Gene Orthologous residues APC1 (human): S355‑p, APC1 (mouse): S355‑p, APC1 (rat): S355‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium), taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), vincristine (preceded by thymidine block, then 4 hr fresh medium)

S362-p - APC1 (human) ▲

Modsite: sPALGVHsFsGVQRF SwissProt Entrez-Gene Orthologous residues APC1 (human): S362‑p, APC1 (mouse): S362‑p, APC1 (rat): S362‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium), taxol, high dose (preceded by thymidine block, then 4 hr fresh medium); ambiguous, taxol, low dose (preceded by thymidine block, then 4 hr fresh medium); ambiguous

S377-p - APC1 (human) ▲

Modsite: NIssHNQsPkRHSIS SwissProt Entrez-Gene Orthologous residues APC1 (human): S377‑p, APC1 (mouse): S377‑p, APC1 (rat): S377‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium), nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes taxol increase

T530-p - APC1 (human) ▲

Modsite: NtMPRPstPLDGVst SwissProt Entrez-Gene Orthologous residues APC1 (human): T530‑p, APC1 (mouse): T530‑p, APC1 (rat): T530‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  S-phase (thymidine block, release into S), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium)

T537-p - APC1 (human) ▲
Modsite: tPLDGVstPkPLsKL SwissProt Entrez-Gene Orthologous residues APC1 (human): T537‑p, APC1 (mouse): T537‑p, APC1 (rat): T537‑p

S542-p - APC1 (human) ▲

Modsite: VstPkPLsKLLGsLD SwissProt Entrez-Gene Orthologous residues APC1 (human): S542‑p, APC1 (mouse): S542‑p, APC1 (rat): S542‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  vincristine (preceded by thymidine block, then 4 hr fresh medium)

S555-p - APC1 (human) ▲

Modsite: LDEVVLLsPVPELRD SwissProt Entrez-Gene Orthologous residues APC1 (human): S555‑p, APC1 (mouse): S555‑p, APC1 (rat): S555‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium)

S564-p - APC1 (human) ▲

Modsite: VPELRDsskLHDsLy SwissProt Entrez-Gene Orthologous residues APC1 (human): S564‑p, APC1 (mouse): S564‑p, APC1 (rat): S564‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  monastrol (preceded by thymidine block, then 4 hr fresh medium)

S600-p - APC1 (human) ▲

Modsite: NRVtLELsNGSMVRI SwissProt Entrez-Gene Orthologous residues APC1 (human): S600‑p, APC1 (mouse): S600‑p, APC1 (rat): S600‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium), vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase

S688-p - APC1 (human) ▲

Modsite: FDFEGsLsPVIAPkk SwissProt Entrez-Gene Orthologous residues APC1 (human): S688‑p, APC1 (mouse): S688‑p, APC1 (rat): S688‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase

S731-p - APC1 (human) ▲

Modsite: LNRsLCLsPSEASQM SwissProt Entrez-Gene Orthologous residues APC1 (human): S731‑p, APC1 (mouse): T731‑p, APC1 (rat): N731‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  monastrol (preceded by thymidine block, then 4 hr fresh medium), nocodazole (preceded by thymidine block, then 4 hr fresh medium), taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium), vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes vincristine increase

Y1552-p - APC1 (human) ▲

Modsite: KTGGEMNyGFHLAHH SwissProt Entrez-Gene Orthologous residues APC1 (human): Y1552‑p, APC1 (mouse): Y1552‑p, APC1 (rat): Y1552‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  taxol, high dose (preceded by thymidine block, then 4 hr fresh medium)

S1707-p - APC1 (human) ▲

Modsite: kLRAGQLsYkEDPMG SwissProt Entrez-Gene Orthologous residues APC1 (human): S1707‑p, APC1 (mouse): S1707‑p, APC1 (rat): S1707‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium)

T3-p - APC10 (human) ▲

Modsite: _____MttPNktPPG SwissProt Entrez-Gene Orthologous residues APC10 (human): T3‑p, APC10 (mouse): T3‑p, APC10 (rat): T3‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  taxol, high dose (preceded by thymidine block, then 4 hr fresh medium)

S218-p - APC2 (human) ▲

Modsite: RYYRLLQsPLCAGCS SwissProt Entrez-Gene Orthologous residues APC2 (human): S218‑p, APC2 iso2 (human): S218‑p, APC2 (mouse): S233‑p, APC2 (rat): ‑ Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes taxol increase

S314-p - APC2 (human) ▲

Modsite: DGPARPAsPEAGNtL SwissProt Entrez-Gene Orthologous residues APC2 (human): S314‑p, APC2 iso2 (human): S314‑p, APC2 (mouse): S329‑p, APC2 (rat): S31‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes taxol increase

S354-p - APC2 (human) ▲

Modsite: IVRDFPDsRPAIEDL SwissProt Entrez-Gene Orthologous residues APC2 (human): S354‑p, APC2 iso2 (human): S351‑p, APC2 (mouse): S369‑p, APC2 (rat): S71‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  monastrol (preceded by thymidine block, then 4 hr fresh medium)

T393-p - APC2 (human) ▲

Modsite: LLHPGVNtCDIITLY SwissProt Entrez-Gene Orthologous residues APC2 (human): T393‑p, APC2 iso2 (human): T390‑p, APC2 (mouse): T408‑p, APC2 (rat): T110‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium)

S532-p - APC2 (human) ▲

Modsite: DRLLHQFsFsPEREI SwissProt Entrez-Gene Orthologous residues APC2 (human): S532‑p, APC2 iso2 (human): S529‑p, APC2 (mouse): S547‑p, APC2 (rat): S249‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes monastrol decrease

S534-p - APC2 (human) ▲

Modsite: LLHQFsFsPEREIRN SwissProt Entrez-Gene Orthologous residues APC2 (human): S534‑p, APC2 iso2 (human): S531‑p, APC2 (mouse): S549‑p, APC2 (rat): S251‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase

S777-p - APC4 (human) ▲

Modsite: KIkEEVLsEsEAENQ SwissProt Entrez-Gene Orthologous residues APC4 (human): S777‑p, APC4 iso3 (human): S778‑p, APC4 (mouse): S777‑p, APC4 (rat): S777‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M), monastrol (preceded by thymidine block, then 4 hr fresh medium), nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium), vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase

T15-p - APC5 (human) ▲

Modsite: LYFNPMMtNGVVHAN SwissProt Entrez-Gene Orthologous residues APC5 (human): T15‑p, APC5 iso2 (human): ‑, APC5 (mouse): T3‑p, APC5 (rat): T3‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M), taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), vincristine (preceded by thymidine block, then 4 hr fresh medium)

S195-p - APC5 (human) ▲

Modsite: EKEELDVsVREEEVS SwissProt Entrez-Gene Orthologous residues APC5 (human): S195‑p, APC5 iso2 (human): S74‑p, APC5 (mouse): S180‑p, APC5 (rat): S180‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  monastrol (preceded by thymidine block, then 4 hr fresh medium), taxol, high dose (preceded by thymidine block, then 4 hr fresh medium)

S221-p - APC5 (human) ▲

Modsite: FFLsQQAsLLkNDET SwissProt Entrez-Gene Orthologous residues APC5 (human): S221‑p, APC5 iso2 (human): S100‑p, APC5 (mouse): A206‑p, APC5 (rat): A206‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase

T232-p - APC5 (human) ▲

Modsite: NDETkALtPAsLQkE SwissProt Entrez-Gene Orthologous residues APC5 (human): T232‑p, APC5 iso2 (human): T111‑p, APC5 (mouse): T217‑p, APC5 (rat): T217‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes thymidine increase

S674-p - APC5 (human) ▲

Modsite: VAkCQVAsAASYDQP SwissProt Entrez-Gene Orthologous residues APC5 (human): S674‑p, APC5 iso2 (human): ‑, APC5 (mouse): S659‑p, APC5 (rat): S646‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  monastrol (preceded by thymidine block, then 4 hr fresh medium), nocodazole (preceded by thymidine block, then 4 hr fresh medium), taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), vincristine (preceded by thymidine block, then 4 hr fresh medium)

S24-p - APC7 (human) ▲

Modsite: sNVRLLssLLLtMsN SwissProt Entrez-Gene Orthologous residues APC7 (human): S24‑p, APC7 (mouse): S24‑p, APC7 (rat): S24‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  vincristine (preceded by thymidine block, then 4 hr fresh medium)

T28-p - APC7 (human) ▲

Modsite: LLssLLLtMsNNNPE SwissProt Entrez-Gene Orthologous residues APC7 (human): T28‑p, APC7 (mouse): T28‑p, APC7 (rat): T28‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  vincristine (preceded by thymidine block, then 4 hr fresh medium)

S30-p - APC7 (human) ▲

Modsite: ssLLLtMsNNNPELF SwissProt Entrez-Gene Orthologous residues APC7 (human): S30‑p, APC7 (mouse): S30‑p, APC7 (rat): S30‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  vincristine (preceded by thymidine block, then 4 hr fresh medium)

T92-p - APC7 (human) ▲

Modsite: stGNsAstPQsQCLP SwissProt Entrez-Gene Orthologous residues APC7 (human): T92‑p, APC7 (mouse): T92‑p, APC7 (rat): T92‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  taxol, high dose (preceded by thymidine block, then 4 hr fresh medium)

S367-p - BUB1B (human) ▲

Modsite: PSINHILstRkPGKE SwissProt Entrez-Gene Orthologous residues BUB1B (human): S367‑p, BUB1B iso2 (human): S313‑p, BUB1B iso3 (human): S381‑p, BUB1B (mouse): S360‑p, BUB1B (rat): S360‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  taxol, low dose (preceded by thymidine block, then 4 hr fresh medium)

S435-p - BUB1B (human) ▲

Modsite: REAELLtsAEkRAEM SwissProt Entrez-Gene Orthologous residues BUB1B (human): S435‑p, BUB1B iso2 (human): S381‑p, BUB1B iso3 (human): S449‑p, BUB1B (mouse): S428‑p, BUB1B (rat): S428‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  vincristine (preceded by thymidine block, then 4 hr fresh medium)

S543-p - BUB1B (human) ▲

Modsite: LsEkKNksPPADPPR SwissProt Entrez-Gene Orthologous residues BUB1B (human): S543‑p, BUB1B iso2 (human): S494‑p, BUB1B iso3 (human): S557‑p, BUB1B (mouse): S535‑p, BUB1B (rat): S535‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium), vincristine (preceded by thymidine block, then 4 hr fresh medium)

S670-p - BUB1B (human) ▲

Modsite: TLsIkkLsPIIEDsR SwissProt Entrez-Gene Orthologous residues BUB1B (human): S670‑p, BUB1B iso2 (human): ‑, BUB1B iso3 (human): S684‑p, BUB1B (mouse): S659‑p, BUB1B (rat): S659‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium), taxol, high dose (preceded by thymidine block, then 4 hr fresh medium)

S1043-p - BUB1B (human) ▲

Modsite: WkVGkLtsPGALLFQ SwissProt Entrez-Gene Orthologous residues BUB1B (human): S1043‑p, BUB1B iso2 (human): S926‑p, BUB1B iso3 (human): S1057‑p, BUB1B (mouse): S1033‑p, BUB1B (rat): S1033‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  monastrol (preceded by thymidine block, then 4 hr fresh medium), nocodazole (preceded by thymidine block, then 4 hr fresh medium)

S560-p - CDC16 (human) ▲

Modsite: kTLkNIIsPPWDFRE SwissProt Entrez-Gene Orthologous residues CDC16 (human): S560‑p, CDC16 (mouse): S560‑p, CDC16 (rat): S560‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase vincristine increase

T581-p - CDC16 (human) ▲

Modsite: TAEETGLtPLETsRK SwissProt Entrez-Gene Orthologous residues CDC16 (human): T581‑p, CDC16 (mouse): A581‑p, CDC16 (rat): A581‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  G1-phase (thymidine block, nocodazole, then 4 hr release into G1), M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase thymidine increase

S586-p - CDC16 (human) ▲

Modsite: GLtPLETsRKtPDSR SwissProt Entrez-Gene Orthologous residues CDC16 (human): S586‑p, CDC16 (mouse): S586‑p, CDC16 (rat): A586‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase thymidine increase

S41-p - CDC20 (human) ▲

Modsite: EAAGPAPsPMRAANR SwissProt Entrez-Gene Orthologous residues CDC20 (human): S41‑p, CDC20 (mouse): S41‑p, CDC20 (rat): S41‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium)

S92-p - CDC20 (human) ▲

Modsite: AAQMEVAsFLLSkEN SwissProt Entrez-Gene Orthologous residues CDC20 (human): S92‑p, CDC20 (mouse): S92‑p, CDC20 (rat): S92‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium)

S284-p - CDC23 (human) ▲

Modsite: RDIDkALsIFNELRk SwissProt Entrez-Gene Orthologous residues CDC23 (human): S284‑p, CDC23 (mouse): S284‑p, CDC23 (rat): S284‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  monastrol (preceded by thymidine block, then 4 hr fresh medium)

T562-p - CDC23 (human) ▲

Modsite: QLRNQGEtPttEVPA SwissProt Entrez-Gene Orthologous residues CDC23 (human): T562‑p, CDC23 (mouse): T562‑p, CDC23 (rat): T562‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M), monastrol (preceded by thymidine block, then 4 hr fresh medium), nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium), vincristine (preceded by thymidine block, then 4 hr fresh medium) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase

T565-p - CDC23 (human) ▲

Modsite: NQGEtPttEVPAPFF SwissProt Entrez-Gene Orthologous residues CDC23 (human): T565‑p, CDC23 (mouse): S565‑p, CDC23 (rat): S565‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium)

S578-p - CDC23 (human) ▲

Modsite: FFLPAsLsANNtPtR SwissProt Entrez-Gene Orthologous residues CDC23 (human): S578‑p, CDC23 (mouse): S578‑p, CDC23 (rat): S578‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  monastrol (preceded by thymidine block, then 4 hr fresh medium)

T582-p - CDC23 (human) ▲

Modsite: AsLsANNtPtRRVsP SwissProt Entrez-Gene Orthologous residues CDC23 (human): T582‑p, CDC23 (mouse): T582‑p, CDC23 (rat): T582‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  vincristine (preceded by thymidine block, then 4 hr fresh medium)

S588-p - CDC23 (human) ▲

Modsite: NtPtRRVsPLNLssV SwissProt Entrez-Gene Orthologous residues CDC23 (human): S588‑p, CDC23 (mouse): S588‑p, CDC23 (rat): S588‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  G1-phase (thymidine block, nocodazole, then 4 hr release into G1), M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes vincristine increase taxol increase

T596-p - CDC23 (human) ▲

Modsite: PLNLssVtP______ SwissProt Entrez-Gene Orthologous residues CDC23 (human): T596‑p, CDC23 (mouse): T596‑p, CDC23 (rat): T596‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  G1-phase (thymidine block, nocodazole, then 4 hr release into G1), M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes vincristine increase taxol increase

T203-p - CDC27 (human) ▲

Modsite: RQPEtVLtEtPQDtI SwissProt Entrez-Gene Orthologous residues CDC27 (human): T203‑p, CDC27 iso2 (human): T203‑p, CDC27 (mouse): T203‑p, CDC27 iso2 (mouse): T184‑p, CDC27 (rat): T203‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium), vincristine (preceded by thymidine block, then 4 hr fresh medium)

T205-p - CDC27 (human) ▲

Modsite: PEtVLtEtPQDtIEL SwissProt Entrez-Gene Orthologous residues CDC27 (human): T205‑p, CDC27 iso2 (human): T205‑p, CDC27 (mouse): T205‑p, CDC27 iso2 (mouse): T186‑p, CDC27 (rat): T205‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase

S219-p - CDC27 (human) ▲
Modsite: LNRLNLEssNsKYSL SwissProt Entrez-Gene Orthologous residues CDC27 (human): S219‑p, CDC27 iso2 (human): S219‑p, CDC27 (mouse): S219‑p, CDC27 iso2 (mouse): S200‑p, CDC27 (rat): S219‑p

S220-p - CDC27 (human) ▲

Modsite: NRLNLEssNsKYSLN SwissProt Entrez-Gene Orthologous residues CDC27 (human): S220‑p, CDC27 iso2 (human): S220‑p, CDC27 (mouse): S220‑p, CDC27 iso2 (mouse): S201‑p, CDC27 (rat): S220‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); ambiguous, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes taxol decrease

S222-p - CDC27 (human) ▲
Modsite: LNLEssNsKYSLNTD SwissProt Entrez-Gene Orthologous residues CDC27 (human): S222‑p, CDC27 iso2 (human): S222‑p, CDC27 (mouse): S222‑p, CDC27 iso2 (mouse): S203‑p, CDC27 (rat): S222‑p

T264-p - CDC27 (human) ▲

Modsite: QVQNKPKtGRSLLGG SwissProt Entrez-Gene Orthologous residues CDC27 (human): T264‑p, CDC27 iso2 (human): T264‑p, CDC27 (mouse): T264‑p, CDC27 iso2 (mouse): T245‑p, CDC27 (rat): T264‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M), monastrol (preceded by thymidine block, then 4 hr fresh medium), nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium), vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site

S334-p - CDC27 (human) ▲

Modsite: TGtkSVFsQsGNsRE SwissProt Entrez-Gene Orthologous residues CDC27 (human): S334‑p, CDC27 iso2 (human): S340‑p, CDC27 (mouse): S334‑p, CDC27 iso2 (mouse): S315‑p, CDC27 (rat): S334‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes vincristine increase nocodazole increase

S336-p - CDC27 (human) ▲

Modsite: tkSVFsQsGNsREVt SwissProt Entrez-Gene Orthologous residues CDC27 (human): S336‑p, CDC27 iso2 (human): S342‑p, CDC27 (mouse): S336‑p, CDC27 iso2 (mouse): S317‑p, CDC27 (rat): S336‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase

T366-p - CDC27 (human) ▲

Modsite: tPQVLsPtItsPPNA SwissProt Entrez-Gene Orthologous residues CDC27 (human): T366‑p, CDC27 iso2 (human): T372‑p, CDC27 (mouse): T367‑p, CDC27 iso2 (mouse): T348‑p, CDC27 (rat): T367‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium), vincristine (preceded by thymidine block, then 4 hr fresh medium); ambiguous

S369-p - CDC27 (human) ▲

Modsite: VLsPtItsPPNALPR SwissProt Entrez-Gene Orthologous residues CDC27 (human): S369‑p, CDC27 iso2 (human): S375‑p, CDC27 (mouse): S370‑p, CDC27 iso2 (mouse): S351‑p, CDC27 (rat): S370‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  nocodazole (preceded by thymidine block, then 4 hr fresh medium)

T383-p - CDC27 (human) ▲

Modsite: RRssRLFtsDssttk SwissProt Entrez-Gene Orthologous residues CDC27 (human): T383‑p, CDC27 iso2 (human): T389‑p, CDC27 (mouse): T384‑p, CDC27 iso2 (mouse): T365‑p, CDC27 (rat): T384‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site

S384-p - CDC27 (human) ▲

Modsite: RssRLFtsDssttkE SwissProt Entrez-Gene Orthologous residues CDC27 (human): S384‑p, CDC27 iso2 (human): S390‑p, CDC27 (mouse): S385‑p, CDC27 iso2 (mouse): S366‑p, CDC27 (rat): S385‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase

S386-p - CDC27 (human) ▲

Modsite: sRLFtsDssttkENs SwissProt Entrez-Gene Orthologous residues CDC27 (human): S386‑p, CDC27 iso2 (human): S392‑p, CDC27 (mouse): S387‑p, CDC27 iso2 (mouse): S368‑p, CDC27 (rat): S387‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M), taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium), vincristine (preceded by thymidine block, then 4 hr fresh medium)

S387-p - CDC27 (human) ▲

Modsite: RLFtsDssttkENsK SwissProt Entrez-Gene Orthologous residues CDC27 (human): S387‑p, CDC27 iso2 (human): S393‑p, CDC27 (mouse): S388‑p, CDC27 iso2 (mouse): S369‑p, CDC27 (rat): S388‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  vincristine (preceded by thymidine block, then 4 hr fresh medium)

T389-p - CDC27 (human) ▲

Modsite: FtsDssttkENsKKL SwissProt Entrez-Gene Orthologous residues CDC27 (human): T389‑p, CDC27 iso2 (human): T395‑p, CDC27 (mouse): T390‑p, CDC27 iso2 (mouse): T371‑p, CDC27 (rat): T390‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  vincristine (preceded by thymidine block, then 4 hr fresh medium)

S426-p - CDC27 (human) ▲

Modsite: TQPNINDsLEItkLD SwissProt Entrez-Gene Orthologous residues CDC27 (human): S426‑p, CDC27 iso2 (human): S432‑p, CDC27 (mouse): S427‑p, CDC27 iso2 (mouse): ‑, CDC27 (rat): S427‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  G1-phase (thymidine block, nocodazole, then 4 hr release into G1), M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase thymidine decrease

S435-p - CDC27 (human) ▲

Modsite: EItkLDssIIsEGkI SwissProt Entrez-Gene Orthologous residues CDC27 (human): S435‑p, CDC27 iso2 (human): S441‑p, CDC27 (mouse): S436‑p, CDC27 iso2 (mouse): ‑, CDC27 (rat): S436‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole decrease monastrol decrease

S438-p - CDC27 (human) ▲

Modsite: kLDssIIsEGkIStI SwissProt Entrez-Gene Orthologous residues CDC27 (human): S438‑p, CDC27 iso2 (human): S444‑p, CDC27 (mouse): S439‑p, CDC27 iso2 (mouse): ‑, CDC27 (rat): S439‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes monastrol decrease

T444-p - CDC27 (human) ▲

Modsite: IsEGkIStItPQIQA SwissProt Entrez-Gene Orthologous residues CDC27 (human): T444‑p, CDC27 iso2 (human): T450‑p, CDC27 (mouse): T445‑p, CDC27 iso2 (mouse): ‑, CDC27 (rat): T445‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  monastrol (preceded by thymidine block, then 4 hr fresh medium), nocodazole (preceded by thymidine block, then 4 hr fresh medium), taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium)

T446-p - CDC27 (human) ▲

Modsite: EGkIStItPQIQAFN SwissProt Entrez-Gene Orthologous residues CDC27 (human): T446‑p, CDC27 iso2 (human): T452‑p, CDC27 (mouse): T447‑p, CDC27 iso2 (mouse): ‑, CDC27 (rat): T447‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  G1-phase (thymidine block, nocodazole, then 4 hr release into G1), M-phase (thymidine block, 8 hr fresh medium, then release into M); quantitation of phosporylated peptide vs unphosphorylated peptide for site, monastrol (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, nocodazole (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, taxol, high dose (preceded by thymidine block, then 4 hr fresh medium), taxol, low dose (preceded by thymidine block, then 4 hr fresh medium), taxol, medium dose (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site, vincristine (preceded by thymidine block, then 4 hr fresh medium); quantitation of phosporylated peptide vs unphosphorylated peptide for site Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nocodazole increase

S553-p - CDC27 (human) ▲

Modsite: LQKDVALsVLSkDLT SwissProt Entrez-Gene Orthologous residues CDC27 (human): S553‑p, CDC27 iso2 (human): S559‑p, CDC27 (mouse): S554‑p, CDC27 iso2 (mouse): ‑, CDC27 (rat): S553‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  monastrol (preceded by thymidine block, then 4 hr fresh medium)

T691-p - CDC27 (human) ▲

Modsite: KSEkALDtLNkAIVI SwissProt Entrez-Gene Orthologous residues CDC27 (human): T691‑p, CDC27 iso2 (human): T697‑p, CDC27 (mouse): T692‑p, CDC27 iso2 (mouse): ‑, CDC27 (rat): T691‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Comments:  vincristine (preceded by thymidine block, then 4 hr fresh medium)